<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35491102</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1347-3700</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell structure and function</Title>
          <ISOAbbreviation>Cell Struct Funct</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A method for the generation of pseudovirus particles bearing SARS coronavirus spike protein in high yields.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1247/csf.21047</ELocationID>
        <Abstract>
          <AbstractText>The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has threatened human health and the global economy. Development of additional vaccines and therapeutics is urgently required, but such development with live virus must be conducted with biosafety level 3 confinement. Pseudotyped viruses have been widely adopted for studies of virus entry and pharmaceutical development to overcome this restriction. Here we describe a modified protocol to generate vesicular stomatitis virus (VSV) pseudotyped with SARS-CoV or SARS-CoV-2 spike protein in high yield. We found that a large proportion of pseudovirions produced with the conventional transient expression system lacked coronavirus spike protein at their surface as a result of inhibition of parental VSV infection by overexpression of this protein. Establishment of stable cell lines with an optimal expression level of coronavirus spike protein allowed the efficient production of progeny pseudoviruses decorated with spike protein. This improved VSV pseudovirus production method should facilitate studies of coronavirus entry and development of antiviral agents.Keywords: severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, pseudovirus, vesicular stomatitis virus (VSV), spike protein.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fujioka</LastName>
            <ForeName>Yoichiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Global Station for Biosurfaces and Drug Discovery, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kashiwagi</LastName>
            <ForeName>Sayaka</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Global Station for Biosurfaces and Drug Discovery, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshida</LastName>
            <ForeName>Aiko</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Global Station for Biosurfaces and Drug Discovery, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Satoh</LastName>
            <ForeName>Aya O</ForeName>
            <Initials>AO</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fujioka</LastName>
            <ForeName>Mari</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amano</LastName>
            <ForeName>Maho</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamauchi</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Cellular and Molecular Medicine, University of Bristol.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Biological Science, Graduate School of Science, Nagoya University.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ohba</LastName>
            <ForeName>Yusuke</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Physiology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Global Station for Biosurfaces and Drug Discovery, Hokkaido University.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>AMED-CREST, Japan Agency for Medical Research and Development.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Japan</Country>
        <MedlineTA>Cell Struct Funct</MedlineTA>
        <NlmUniqueID>7608465</NlmUniqueID>
        <ISSNLinking>0386-7196</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">pseudovirus</Keyword>
        <Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus (SARS-CoV)</Keyword>
        <Keyword MajorTopicYN="N">spike protein</Keyword>
        <Keyword MajorTopicYN="N">vesicular stomatitis virus (VSV)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>21</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35491102</ArticleId>
        <ArticleId IdType="doi">10.1247/csf.21047</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
